BEGIN:VCALENDAR
VERSION:2.0
CALSCALE:GREGORIAN
PRODID:iCalendar-Ruby
BEGIN:VEVENT
CATEGORIES:Grand Rounds,Research,Faculty
DESCRIPTION:“Breaking New Ground in Parathyroid Hormone-Related Treatments”
 \n\n \n\nSpeaker:\n\nMichael Mannstadt\, M.D.\nChief of the Endocrine Unit\
 nAssociate Professor in Medicine\, Harvard Medical School\nMassachusetts G
 eneral Hospital\n\n \n\nAbout Michael Mannstadt:\n\nDr. Mannstadt earned hi
 s medical degree from Jena University in Germany. He then completed interna
 l medicine residency training\, followed by a clinical fellowship in endocr
 inology\, diabetes and metabolism\, at Massachusetts General Hospital and H
 arvard Medical School. \n\n \n\nDr. Mannstadt's clinical interests include 
 disorders of mineral metabolism and bone diseases. His research concentrate
 s on the basic and translational aspects of parathyroid hormone with a part
 icular interest in hypoparathyroidism. \n\n \n\nHe is a Board Certified End
 ocrinologist who serves as Chief of the Endocrine Unit at Massachusetts Gen
 eral Hospital and Associate Professor in Medicine\, Harvard Medical School\
 , both in Boston.\n\n \n\nDr. Mannstadt established his laboratory within t
 he Endocrine Unit of Massachusetts General Hospital. His research focuses o
 n parathyroid function and disease including (1) understanding the genetic 
 basis of familial hypoparathyroidism\; (2) defining the mechanisms by which
  the newly identified genes and pathways impact parathyroid function\; (3) 
 using these insights to improve treatment for parathyroid disorders. His ba
 sic research also investigates the transcriptional network of parathyroid c
 ells. His clinical research focuses in particular on hypoparathyroidism and
  his research group analyzed one of the largest patient series in hypoparat
 hyroidism. This study reveals significant shortcomings of our current thera
 py. Recognizing the limitations of current therapies\, he became the Princi
 pal Investigator of an NIH grant for the development of a long-acting PTH\,
  and is the lead author of the phase 3 clinical trial of PTH(1-84) in hypop
 arathyroidism. He is a Medical Advisor for the Hypoparathyroid Association 
 and a frequent faculty participant at their annual patient meetings. He has
  participated in the development of guidelines for the management of hypopa
 rathyroidism. \n\n \n\nVisit the Mannstadt Lab
DTEND:20240510T140000Z
DTSTAMP:20260308T104026Z
DTSTART:20240510T130000Z
GEO:32.81271;-96.841312
LOCATION:Eugene McDermott Plaza and Lecture Halls (D)\, D1.502
SEQUENCE:0
SUMMARY:Michael Mannstadt\, M.D. | Internal Medicine Grand Rounds
UID:tag:localist.com\,2008:EventInstance_46244458211672
URL:https://events.utsouthwestern.edu/event/mannstadt_051024
END:VEVENT
END:VCALENDAR